Navigation Links
NPS Pharmaceuticals Announces Senior Management Changes

BEDMINSTER, N.J., Feb. 26 /PRNewswire-FirstCall/ -- NPS Pharmaceuticals, Inc. (Nasdaq: NPSP) announced today that Dr. Tony Coles will be stepping down from his positions as president, chief executive officer and a director effective March 17, 2008 to become president, chief executive officer and a director of Onyx Pharmaceuticals, Inc. (Nasdaq: ONXX). He will be succeeded by NPS executive vice president and chief operating officer Dr. Francois Nader, who will become president and chief executive officer of NPS.

NPS chairman Peter Tombros stated: "On behalf of the NPS board, I wish Tony much success in his new position and congratulate Francois on his promotion. Francois has been instrumental in developing our new business plan and we are confident that he will lead NPS successfully in the years ahead. He is uniquely well-qualified to guide NPS because of his demonstrated expertise in clinical research and corporate strategy, his many years of pharmaceutical industry experience and his superb management skills. I am confident that he will be a very effective chief executive as the company focuses on executing an ambitious clinical program.

"I also thank Tony for his outstanding service during a challenging period in the company's history. Under his leadership, we shifted our business plan to focus on developing our late-stage products in new specialty indications, raised a significant amount of cash to fund these pipeline investments and consolidated our long-term debt to strengthen the company's balance sheet. We appreciate his lasting contributions to NPS and wish him well in his future endeavors."

Dr. Nader stated: "I appreciate the board's confidence in me to lead NPS and look forward to building upon the vision and strategy we defined last year. With the completion of our restructuring and recapitalization in 2007, NPS has the necessary human and financial resources to maximize the value of its late-stage assets. I am excited about our opportunities to help patients and create value for shareholders, and join Peter in offering our best wishes to Tony in his new position and our sincere thanks for his leadership at NPS."

Dr. Nader joined NPS in 2006 as chief medical and commercial officer. He was promoted to executive vice president and chief operating officer in 2007 and appointed to the NPS board of directors in January 2008. Previously, he was a venture partner at Care Capital, LLC and chief medical officer of its Clinical Development Capital unit. He was also senior vice president, integrated healthcare markets and North America medical and regulatory affairs with Aventis Pharmaceuticals, and held similar positions at Hoechst Marion Roussel and its predecessor companies. Before joining Hoechst Marion Roussel, Dr. Nader served as head of global commercial operations at the Pasteur Vaccines division of Rhone-Poulenc.

Conference Call Information

A conference call will be held today at 10:00 a.m. Eastern Time. To participate in the call, dial (800) 659-1966 with pass code 85375871. International callers may dial (617) 614-2711 and use the same pass code. The conference call is also available as a webcast, which can be accessed on the company's home page, A conference call replay will be available until March 4, 2008. To access the replay, dial (888) 286-8010 or (617) 801-6888 for international callers, with pass code 19985458. The webcast will be available for iPod(R) download for the same period.

About NPS Pharmaceuticals

NPS Pharmaceuticals is developing high value specialty therapeutics for gastrointestinal and endocrine disorders. The company is currently advancing two late-stage programs: GATTEX(TM) (teduglutide) is in Phase 3 clinical development for intestinal failure associated with short bowel syndrome and parathyroid hormone 1-84 [rDNA origin] injection is in Phase 2 clinical development as a hormone therapy for hypoparathyroidism (parathyroid hormone 1-84 [rDNA origin] injection). NPS has also completed a Phase 3 osteoporosis study for PREOS(R) (parathyroid hormone 1-84 [rDNA origin] injection). NPS complements its internal programs with strategic partnerships, which include Amgen, GlaxoSmithKline, Kirin, and Nycomed. Additional information is available at

Statements made in this press release, which are not historical in nature, constitute forward-looking statements for purposes of the safe harbor provided by the Private Securities Litigation Reform Act of 1995. These statements are based on the company's current expectations and beliefs and are subject to a number of factors and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements. Risks associated to NPS's business include, but are not limited to, the risk of successfully advancing its preclinical and clinical pipeline and gaining marketing approvals for its product candidates, as well as other factors expressed in NPS's periodic filings with the U.S. Securities and Exchange Commission, including its Annual Report on Form 10-K and Form 10-Qs. All information in this press release is as of the date of this release and NPS undertakes no duty to update this information.

SOURCE NPS Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. Neurobiological Technologies Announces Amendment of License and Cooperation Agreement with Merz Pharmaceuticals and Childrens Hospital
2. Strativa Pharmaceuticals, a Division of Par Pharmaceutical, Announces the Discontinuation of the Development Program for Pafuramidine
3. Keryx Biopharmaceuticals, Inc. Announces Fourth Quarter and Year-End 2007 Financial Results
4. Keryx Biopharmaceuticals, Inc. to Hold Conference Call on Fourth Quarter and Year-End 2007 Financial Results on Monday, February 25, at 8:30 A.M. EST
5. Nycomed US Inc. Acquires Bradley Pharmaceuticals, Inc.
6. Cadence Pharmaceuticals Completes $49.3 Million Registered Direct Offering
7. Addrenex Pharmaceuticals Reaches Milestone with Filing of NDA for First Product, CloniBID, to Treat Hypertension
8. Vion Pharmaceuticals to Implement a One-for-Ten Reverse Stock Split
9. Sunesis Pharmaceuticals Announces Milestone Payment from Inflammation Collaboration
10. Arena Pharmaceuticals to Report Fourth Quarter and Full Year 2007 Financial Results and to Host Conference Call and Webcast on Wednesday, February 27, 2008
11. Watson Pharmaceuticals Reports Fourth Quarter and Full Year 2007 Results; Provides 2008 Outlook
Post Your Comments:
(Date:11/24/2015)... DIEGO , Nov. 24, 2015 Halozyme Therapeutics, Inc. ... Healthcare Conference in New York on Wednesday, ... Helen Torley , president and CEO, will provide a corporate ... New York at 1:00 p.m. ET/10:00 a.m. PT ... and investor relations, will provide a corporate overview. --> ...
(Date:11/24/2015)... /PRNewswire/ - Aeterna Zentaris Inc. (NASDAQ:  AEZS) (TSX: AEZ) (the ... the Toronto Stock Exchange, confirms that as of the ... developments that would cause the recent movements in the ... --> About Aeterna Zentaris Inc. ... Aeterna Zentaris is a specialty biopharmaceutical company engaged in ...
(Date:11/24/2015)... ... ... The Academy of Model Aeronautics (AMA), led by its Executive Council, has officially ... to represent the First–Person View (FPV) racing community. , FPV racing has exploded in ... racing and several new model aviation pilots have joined the community because of their ...
(Date:11/24/2015)... , Nov. 24, 2015 /PRNewswire/ - Aeterna ... announced today that the remaining 11,000 post-share consolidation ... Purchase Warrants (the "Series B Warrants") subject to ... exercised on November 23, 2015, which will result ... After giving effect to the issuance of such ...
Breaking Biology Technology:
(Date:10/26/2015)... , October 26, 2015 /PRNewswire/ ... --> adds Biometrics ... to 2021 as well as Emerging ... research reports to its collection of ... . --> ...
(Date:10/23/2015)... 23, 2015 Research and Markets ( ... Voice Recognition Biometrics Market 2015-2019" report to their ... The global voice recognition biometrics market to grow ... --> --> The report, ... based on an in-depth market analysis with inputs from ...
(Date:10/22/2015)... JOSE, Calif., Oct. 22, 2015  Synaptics (NASDAQ: SYNA ), ... for its first quarter ended September 30, 2015. ... quarter of fiscal 2016 grew 66 percent over the comparable quarter ... of fiscal 2016 was $23.8 million, or $0.62 per diluted share. ... income for the first quarter of fiscal 2016 grew 39 percent ...
Breaking Biology News(10 mins):